| Title |
Clozapine versus typical neuroleptic medication for schizophrenia
|
|---|---|
| Published in |
Cochrane database of systematic reviews, January 2009
|
| DOI | 10.1002/14651858.cd000059.pub2 |
| Pubmed ID | |
| Authors |
Adib Essali, Nahla Al‐Haj Haasan, Chunbo Li, John Rathbone |
| Abstract |
Long-term drug treatment of schizophrenia with typical antipsychotics has limitations: 25 to 33% of patients have illnesses that are treatment-resistant. Clozapine is an antipsychotic drug, which is claimed to have superior efficacy and to cause fewer motor adverse effects than typical drugs for people with treatment-resistant illnesses. Clozapine carries a significant risk of serious blood disorders, which necessitates mandatory weekly blood monitoring at least during the first months of treatment. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 50% |
| Austria | 1 | 17% |
| Chile | 1 | 17% |
| Unknown | 1 | 17% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 581 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | <1% |
| Germany | 2 | <1% |
| United States | 2 | <1% |
| Spain | 2 | <1% |
| Chile | 1 | <1% |
| United Kingdom | 1 | <1% |
| Australia | 1 | <1% |
| Portugal | 1 | <1% |
| Brazil | 1 | <1% |
| Other | 0 | 0% |
| Unknown | 568 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 95 | 16% |
| Student > Master | 79 | 14% |
| Student > Ph. D. Student | 59 | 10% |
| Student > Bachelor | 57 | 10% |
| Student > Doctoral Student | 40 | 7% |
| Other | 130 | 22% |
| Unknown | 121 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 194 | 33% |
| Psychology | 77 | 13% |
| Nursing and Health Professions | 44 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 23 | 4% |
| Neuroscience | 21 | 4% |
| Other | 79 | 14% |
| Unknown | 143 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 25. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 May 2023.
All research outputs
#1,515,714
of 25,595,500 outputs
Outputs from Cochrane database of systematic reviews
#3,260
of 13,156 outputs
Outputs of similar age
#6,004
of 185,481 outputs
Outputs of similar age from Cochrane database of systematic reviews
#10
of 84 outputs
Altmetric has tracked 25,595,500 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,156 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.8. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 185,481 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 84 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.